目的探讨131I全身扫描（131I-WBS）及18F-FDG PET/CT在分化型甲状腺癌（DTC）术后转移诊治中的临床价值。资料与方法27例DTC术后需行131I初治或复治的患者，检测其131I治疗前1 d的血清甲状腺球蛋白（Tg），在131I治疗后3~5 d进行131I-WBS。根据Tg与131I-WBS阴性或阳性的情况，将患者分成4种类型：I型：Tg（+），131I-WBS（－）；II 型：Tg（+），131I-WBS（+）；III 型：Tg（－），131I-WBS （+）；IV型：Tg（－），131I-WBS（－）。在131I-WBS后1周内行18F-FDG PET/CT。以术后组织病理学或至少6个月的临床和影像学随访结果为诊断病灶性质标准。分析131I-WBS及18F-FDG PET/CT对DTC术后患者转移的检出情况。结果检查后发现有22例52处病灶发生了转移。131I-WBS检出其中的8例（36.4%）24处（46.2%）转移灶，与18F-FDG PET/CT检出的15例（68.2%）35处（67.3%）转移灶比较，差异均有统计学意义（χ2=4.46、4.74, P<0.05）。I型13例（100.0%）、II型5例（100.0%）、III型3例（100.0%）、IV型1例（16.7%）发生了转移。I型18F-FDG PET/CT的转移检出率（100.0%）与II型（20.0%）、III型（0%）比较，差异均有统计学意义（P<0.05），与IV型（100.0%）比较差异无统计学意义（P>0.05）。其中对13例I型和1例IV型转移患者调整了治疗方案。结论131I-WBS和18F-FDG PET/CT在DTC术后患者转移灶探测及决定下一步的治疗方案方面具有良好的互补性，特别是18F-FDG PET/CT在Tg（+）、131I-WBS（－）患者转移灶检出上更具有优势，有重要的临床指导意义。%Purpose To explore the clinical value of131I-whole body scan (131I-WBS) and 18F-FDG PET/CT on the metastatic management of patients with differentiated thyroid cancer (DTC) after operation.Materials and Methods Serum thyroglobulin (Tg) of 27 patients after DTC surgery was measured one day before131I therapy, and the patients underwent131I-WBS on 3-5 days after131I therapy. According to the results of Tg and 131I-WBS, all the patients were divided into 4 types as follows: type I: Tg (+),131I-WBS (-); type II: Tg (+),131I-WBS (+); type III: Tg (-),131I-WBS (+); and type IV: Tg (-), 131I-WBS (-). Then the patients received18F-FDG PET/CT scan within a week after 131I-WBS. The results of131I-WBS and18F-FDG PET/CT scan were analyzed according to histopathologic findings or clinical and imaging follow-up of at least 6 months as diagnosis standard.Results The examinations uncovered that metastasis occurred in 52 lesions of 22 cases out of the 27 cases.131I-WBS revealed 24 metastatic lesions (46.2%) in 8 cases (36.4%), and18F-FDG PET/CT showed 35 metastatic lesions (67.3%) in 15 cases (68.2%), the difference with statistic significance (χ2=4.46 and 4.74,P<0.05). Metastasis were confirmed in 13 type I cases (100.0%); 5 type II cases (100.0%); 3 type III cases (100.0%) and 1 type IV case (16.7%), respectively. The rate of detecting metastasis by 18F-FDG PET/CT was 100.0% in type I, 20.0% in type II, 0% in type III respectively, the difference with statistic significance (χ2=9.14 and 10.11,P<0.05); and 100.0% in type IV, the difference without statistic significance (χ2=1.25,P>0.05). Based on that, therapeutic plans were modified for 13 patients with type I metastasis and 1 patient with type IV metastasis.Conclusion131I-WBS and18F-FDG PET/CT are complementary for detecting metastatic lesion and help to decide the following treatment of DTC patients after surgery. Moreover,18F-FDG PET/CT shows advantages in detecting metastatic lesion in Tg-positive and negative131I-WBS type of DTC patients after surgery, thus can provide an important clinical guidance for this type of patients.
展开▼
